Immuneering Corp Ordinary Shares Class A IMRX 深 沪
已收盘 12-19 16:00:00 美东时间
5.675
+0.005
+0.09%
华盛通- 最 高7.76
- 今 开5.68
- 成交量 144.53万股
- 最 低 5.45
- 昨 收 5.67
- 总市值 1.50亿
- 52周最高 10.08
- 市盈率 静 --
- 换手率 5.48%
- 52周最低 1.10
- 委 比 20.54%
- 总股本 2638.53万
- 历史最高 33.99
- 量 比 1.53
- 振 幅 40.74%
- 历史最低 1.00
- 每 手 1
- 风险率 2.30%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Immuneering To Be Added To Nasdaq Biotechnology Index, Effective December 22
Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that it is expected to be added to the Nasdaq Biotechnology
12-16 21:03
Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients
Immuneering Corporation announced positive Phase 2a data for atebimetinib in combination with modified Gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients, showing 94% overall survival and 72% progression-free survival at 6 months, with a 39% overall response rate. Atebimetinib demonstrated favorable tolerability, with no Grade 3+ events in most adverse event categories. The company plans a pivotal trial for 2026.
06-17 10:00
Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025
Immuneering Corporation will host a conference call on June 17, 2025, at 8:00 am ET to discuss updates from its Phase 2a clinical trial for IMM-1-104 in first-line pancreatic cancer patients.
06-16 12:00
Immuneering to Present at the Jefferies Global Healthcare Conference
Immuneering Corporation's management will present at the Jefferies Global Healthcare Conference on June 5, 2025, to discuss the company's pipeline, platform, and business strategy. The presentation will be webcast live and archived on Immuneering's website.
05-29 12:00
Why Is Nanocap Immuneering Stock Trading Higher On Friday?
Immuneering reported promising initial response data from its Phase 2a trial for IMM-1-104 combined with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer, showing a 40% response rate and 80% disease control rate.
2024-09-13 20:15
Needham Reiterates Buy on Immuneering, Maintains $15 Price Target
Needham analyst Ami Fadia reiterates Immuneering (NASDAQ:IMRX) with a Buy and maintains $15 price target.
2024-09-13 17:42
